Browsing by Author "Abdelaziz, Mahmoud"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Item Amelioration of Autoimmunity and Inflammation by Zinc Oxide Nanoparticles in Experimental Rheumatoid Arthritis(ORCID, 2021-01) Shaaban, Sameh; Fayez, Ahmed M.; Abdelaziz, Mahmoud; Abou El-ezz, DoaaRheumatoid arthritis (RA) is a chronic autoimmune disease that affects the lining of the synovial joints and approximately affects 0.5-1% of the total population imposing a socioeconomic burden. Currently, there is no cure for RA, but receiving proper medical care at early stages of the disease is of high importance, to prevent the progressive disability and premature death. Using rat animal model injected with Complete Freund’s adjuvant proved to be successful in induction of a state highly resembling RA in human. Zinc oxide nanoparticles (ZnO NPs) are considered as one of the most important metal oxide nanoparticles due to their exclusive properties, and they are currently merged in several biological applications due to their biocompatibility, low cost, and high safety prole. In this study, we demonstrated the novel possible benecial effects of using zinc oxide nanoparticles, on such devastating severe disease. Zinc oxide nanoparticles (ZnO NPs) proved to reduce the adjuvant-induced increased productions of IL-1β, TNF-α, IL-10, total leukocyte count, rheumatoid factor, anti-CCP levels in rats, suggesting an interesting option to be available either alone or in combinations to better control RA. In conclusion we recommend the expansion of more in vivo studies to highlight the benets which could be obtained of nanoparticles either alone or in combination with the known anti-arthritic and/or antiinammatory agents; giving rise to new protocols to maximize the control of RAItem Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis(Multidisciplinary Digital Publishing Institute (MDPI), 2022-10) ElBaset, Marwan A; Salem, Rana S; Ayman, Fairouz; Ayman, Nadeen; Shaban, Nooran; Afifi, Sherif M; Esatbeyoglu, Tuba; Abdelaziz, Mahmoud; Elalfy, Zahraa SHepatic fibrosis causes severe morbidity and death. No viable treatment can repair fibrosis and protect the liver until now. We intended to discover the empagliflozin’s (EMPA) hepatoprotective efficacy in thioacetamide (TAA)-induced hepatotoxicity by targeting AMPK/SIRT-1 activity and reducing HIF-1α. Rats were treated orally with EMPA (3 or 6 mg/kg) with TAA (100 mg/kg, IP) thrice weekly for 6 weeks. EMPA in both doses retracted the serum GGT, ALT, AST, ammonia, triglycerides, total cholesterol, and increased serum albumin. At the same time, EMPA (3 or 6 mg/kg) replenished the hepatic content of GSH, ATP, AMP, AMPK, or SIRT-1 and mitigated the hepatic content of MDA, TNF-α, IL-6, NF-κB, or HIF-1α in a dose-dependent manner. Likewise, hepatic photomicrograph stained with hematoxylin and eosin or Masson trichrome stain of EMPA (3 or 6 mg/kg) revealed marked regression of the hepatotoxic effect of TAA with minimal injury. Similarly, in rats given EMPA (3 or 6 mg/kg), the immunohistochemically of hepatic photomicrograph revealed minimal stain of either α-SMA or caspase-3 compared to the TAA group. Therefore, we concluded that EMPA possessed an antifibrotic effect by targeting AMPK/SIRT-1 activity and inhibiting HIF-1α. The present study provided new insight into a novel treatment of liver fibrosis.Item Enhanced In Vivo Wound Healing Efficacy of a Novel Hydrogel Loaded with Copper (II) Schiff Base Quinoline Complex (CuSQ) Solid Lipid Nanoparticles(Multidisciplinary Digital Publishing Institute (MDPI), 2022-08-08) Abou El-ezz, Doaa; Abdel-Rahman, Laila H; Al-Farhan, Badriah Saad; Mostafa, Dalia A; Ayad, Eman G; Basha, Maram T; Abdelaziz, Mahmoud; Abdalla, Ehab MWound dressings created using nanotechnology are known as suitable substrates to speed up the healing of both acute and chronic wounds. Therapeutic substances can be delivered using these materials. In this study, a hydrogel loaded with Cu (II) Schiff base 8-hydroxy quinoline complex (CuSQ) solid lipid nanoparticles (SLN) was formulated to investigate its wound healing potential in an excision wound healing model in rats. The CuSQ SLN were spherical shaped with sizes ranging from 111 to 202 nm and a polydispersity index (PDI) ranging from 0.43 to 0.76, encapsulation efficiency (EE) % between 85 and 88, and zeta potential (ZP) of −11.8 to −40 mV. The formulated hydrogel showed good homogeneity, good stability, and a pH of 6.4 which indicates no skin irritation and had no cytotoxicity on the human skin fibroblast (HSF) cell line. In the in vivo study, animals were placed in five groups: control, standard, plain hydrogel, low dose, and high dose of CuSQ hydrogel. Both doses of CuSQ showed significantly faster healing rates compared to standard and control rats. In addition, the histopathology study showed more collagen, improved angiogenesis, and intact re-epithelization with less inflammation. A significant increase in transforming growth factor-beta1 (TGF-β1) level and increased immune expression of vascular endothelial growth factor (VEGF) by CuSQ treatment validates its role in collagen synthesis, proliferation of fibroblasts and enhancement of angiogenesis. Matrix metalloproteinase-9 (MMP-9) was found to be significantly reduced after CuSQ treatment. Immunohistochemistry of tumor necrosis factor alpha (TNF-α) revealed a marked decrease in inflammation. Thus, we concluded that CuSQ would be a beneficial drug for cutaneous wound healing since it effectively accelerated wound healing through regulation of various cytokines and growth factors.